Kymera Therapeutics, Inc. (KYMR)
| Market Cap | 8.89B |
| Revenue (ttm) | 51.48M |
| Net Income (ttm) | -315.00M |
| Shares Out | 82.26M |
| EPS (ttm) | -3.55 |
| PE Ratio | n/a |
| Forward PE | n/a |
| Dividend | n/a |
| Ex-Dividend Date | n/a |
| Volume | 4,264,234 |
| Open | 114.00 |
| Previous Close | 116.46 |
| Day's Range | 106.95 - 119.04 |
| 52-Week Range | 36.65 - 130.05 |
| Beta | 2.03 |
| Analysts | Strong Buy |
| Price Target | 122.10 (+12.93%) |
| Earnings Date | Aug 10, 2026 |
About KYMR
Kymera Therapeutics, Inc., a clinical-stage biopharmaceutical company, focuses on discovering and developing small molecule therapeutics that selectively degrade disease-causing proteins by harnessing the body’s own natural protein degradation system. It engages in developing KT-621, an oral STAT6 degrader in Phase 2b clinical trials for moderate to severe atopic dermatitis, asthma, COPD, EoE, CRSwNP, CSU, PN, BP, and others; KT-579, an oral IRF5 degrader in Phase 1 trials for autoimmune diseases such as systemic lupus erythematosus, rheumatoid... [Read more]
Financial Performance
In 2025, Kymera Therapeutics's revenue was $39.21 million, a decrease of -16.70% compared to the previous year's $47.07 million. Losses were -$311.35 million, 39.1% more than in 2024.
Financial StatementsAnalyst Forecast
According to 23 analysts, the average rating for KYMR stock is "Strong Buy." The 12-month stock price target is $122.1, which is an increase of 12.93% from the latest price.
News
Kymera Therapeutics price target raised to $129 from $106 at Canaccord
Canaccord analyst Edward Nash raised the firm’s price target on Kymera Therapeutics (KYMR) to $129 from $106 and keeps a Buy rating on the shares. The firm said Kymera announced…
Kymera Therapeutics Stock (KYMR) Soars on Accelerated Clinical Trial Enrollment
Kymera Therapeutics stock gained on Thursday after the company revealed quick enrollment in a clinical trial.
Biotech ETF Index Surges 10% After Rebalance
After a sweeping semi-annual rebalance, the biotech index underlying the ALPS Medical Breakthroughs ETF (SBIO) gained over 10% in just six trading days beginning June 18. Key Takeaways: SBIO's underly...
Kymera Therapeutics rises 18.6%
Kymera Therapeutics (KYMR) is up 18.6%, or $18.58 to $118.45.
Kymera Therapeutics completes enrollment in BROADEN2 trial
Kymera Therapeutics (KYMR) announced it has completed enrollment in the global BROADEN2 Phase 2b trial of KT-621, its first-in-class, oral STAT6 degrader, for the treatment of moderate to severe atopi...
Kymera Therapeutics Completes Enrollment in the Phase 2b BROADEN2 Trial of KT-621 in Atopic Dermatitis with Topline Data by Year-end 2026
BROADEN2 enrollment completed nearly six months ahead of anticipated timelines KT-621 Phase 3 trials in AD planned to initiate by mid-2027 KT-621 BREADTH Phase 2b asthma trial ongoing, with data expec...
Kymera Therapeutics appoints Felix Baker as chairman
Kymera Therapeutics (KYMR) announced the appointment of Felix Baker as chairman of the board of directors. Baker succeeds Bruce Booth, DPhil, who has served as chairman since co-founding Kymera in…
Kymera Therapeutics Appoints Felix J. Baker, Ph.D.
Bruce Booth, DPhil, Co-Founder and Chairman, to remain an Independent Director WATERTOWN, Mass., June 24, 2026 (GLOBE NEWSWIRE) -- Kymera Therapeutics, Inc. (NASDAQ: KYMR), a clinical-stage biopharmac...
Kymera Therapeutics Transcript: AGM 2026
The meeting covered board introductions, three shareholder proposals, and voting procedures. All proposals—including director elections, executive compensation approval, and auditor ratification—were passed. No questions were raised by shareholders.
Kymera Therapeutics participates in a conference call with JPMorgan
JPMorgan holds a conference call with management on June 17 at 2 pm. Webcast Link
Kymera Therapeutics Presents Phase 1 Data in Healthy Japanese Adults for KT-621, a First-in-Class Oral STAT6 Degrader, at the Japanese Dermatological Association Annual Meeting
Oral presentation at JDA features new data from the KT-621 Phase 1 study in healthy Japanese adults, with safety and PK/PD results consistent with previously reported KT-621 clinical studies
Healthcare ETFs: From Broad Exposure to Big Breakthroughs
With AI and space dominating many of the market's most popular investment themes, it can be difficult to find differentiated opportunities. Healthcare is often viewed as one of the more defensive sect...
Kymera Therapeutics Announces First Participant Dosed in Phase 1 Trial of Oral IRAK4 Degrader, KT-485, and Milestone Achievement Under Sanofi Collaboration
First-in-human Phase 1 trial evaluating KT-485 (SAR447971) initiated, triggering a $20 million milestone payment from Sanofi WATERTOWN, Mass., June 09, 2026 (GLOBE NEWSWIRE) -- Kymera Therapeutics, In...
Kymera Therapeutics Slides: Corporate presentation
Kymera Therapeutics has posted slides in relation to its latest quarterly earnings report, which was published on June 9, 2026.
Kymera Therapeutics Appoints Penny Carlson as Senior Vice President, Development Operations
Penny Carlson will oversee global clinical development operations across Kymera's oral immunology portfolio Jeremy Chadwick will retire from his role as Chief Operating Officer WATERTOWN, Mass., June ...
Kymera Therapeutics presents preclinical lupus data for KT-579
Kymera Therapeutics (KYMR) announced the presentation of new preclinical data for KT-579, its potent, selective, oral IRF5 degrader, demonstrating disease-modifying activity in lupus models. In multip...
Kymera Therapeutics Presents New Preclinical Lupus Data for KT-579, First-in-Class, Oral IRF5 Degrader, at EULAR and FOCIS Congresses
KT-579 demonstrated consistent disease-modifying activity comparable or superior to approved and clinically active therapies in multiple preclinical lupus models
Kymera Therapeutics Transcript: Jefferies Global Healthcare Conference 2026
The conference highlighted progress in targeted protein degradation, with KT-621 advancing in global Phase IIb studies for atopic dermatitis and asthma. Strong operational focus, robust safety data, and regulatory momentum position the pipeline for significant impact.
Kymera Therapeutics to Participate in Fireside Chat at the Jefferies Global Healthcare Conference
WATERTOWN, Mass., May 27, 2026 (GLOBE NEWSWIRE) -- Kymera Therapeutics, Inc. (NASDAQ: KYMR), a clinical-stage biopharmaceutical company advancing a new class of oral small molecule degrader medicines ...
Kymera Therapeutics Transcript: RBC Capital Markets Global Healthcare Conference 2026
KT-621 phase IIb studies in atopic dermatitis and asthma are progressing on schedule, with strong enthusiasm and robust safety data supporting advancement. The pipeline includes promising IRF5 and IRAK4 degraders, with lupus prioritized for proof-of-concept and broader indications under consideration.
Kymera Therapeutics Announces Presentations on KT-621, a First-In-Class, Oral STAT6 Degrader, at the Society for Investigative Dermatology and American Thoracic Society Congresses
Late-breaking presentation at SID and featured presentation at the ATS Respiratory Innovation Summit highlight KT-621 BroADen Phase 1b clinical data and potential across Type 2 inflammatory diseases
Kymera Therapeutics Transcript: Bank of America Global Healthcare Conference 2026
Management highlighted progress in targeted protein degradation, focusing on immunology with KT-621 in phase II trials for atopic dermatitis and asthma, and IRF5 in early clinical studies. Differentiation is based on sustained target degradation, with large market opportunities in both adult and pediatric populations. Data readouts for key programs are expected in the next 12–24 months.
Kymera Therapeutics initiated with a Buy at Canaccord
Canaccord analyst Edward Nash initiated coverage of Kymera Therapeutics (KYMR) with a Buy rating and $106 price target
Kymera Therapeutics initiated with a Buy at Canaccord
Canaccord initiated coverage of Kymera Therapeutics (KYMR) with a Buy rating and $106 price target The firm views Kymera as one of the “more cutting-edge technology companies” developing drugs within…
Kymera Therapeutics to Participate in Upcoming May Investor Conferences
WATERTOWN, Mass., May 06, 2026 (GLOBE NEWSWIRE) -- Kymera Therapeutics, Inc. (NASDAQ: KYMR), a clinical-stage biopharmaceutical company advancing a new class of oral small molecule degrader medicines ...